hero image
Dr. Christopher  Overgaard - University Health Network. Toronto, ON, CANADA

Dr. Christopher Overgaard

Clinical Researcher, Toronto General Research Institute | University Health Network

Toronto, ON, CANADA

Dr. Christopher B. Overgaard is an interventional cardiologist at the Peter Munk Cardiac Centre in Toronto.

Media

Publications:

Documents:

Photos:

Dr. Christopher  Overgaard Photo

Videos:

Audio/Podcasts:

Social

Biography

Dr. Christopher Overgaard is an interventional cardiologist and a clinician-investigator at the Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network (UHN).

He is the Clinical Director of the Coronary Intensive Care Unit at Toronto General Hospital and the Medical Director the Cardiac Catheterization Laboratories across UHN.

He is an active clinician and clinical researcher with teaching and administrative duties.

His clinical focus has been on complex coronary disease in the setting of myocardial infarction and cariogenic shock. He also has a clinical interest in patients with kidney disease and coronary artery disease.

Dr. Overgaard is actively involved in many research endeavours in the realm of cardiac intensive care, myocardial protection research and clinical outcomes research.

Industry Expertise (2)

Medical/Dental Practice

Research

Areas of Expertise (4)

Cardiology

Higher Education

Heart Disease and Stroke

Interventional Cardiology

Education (2)

University of Toronto: M.D., Medicine 1999

Queen's University: Master's degree, Respiratory Physiology 1995

Media Appearances (5)

‘TandemHeart’ helps make high-risk heart patients strong enough for surgery

Global News  

2017-04-10

“The TandemHeart device is a very powerful motor that helps support the heart through very complex procedures,” said Dr. Chris Overgaard, an interventional cardiologist at the Peter Munk Cardiac Centre...

view more

Toronto doctors complete first-in-Canada heart procedure without surgery

Bangladesh News  

2017-04-08

Cardiologist Dr Christopher Overgaard said Barton's heart was too weak for open-heart surgery. So, the doctor asked if he'd be interested in trying something new. The TandemHeart takes over for a weak heart when doctors are working on it like fixing a car engine while it’s running, Overgaard said. “It acts as an artificial pump, sucking the blood out of the body – energising it, then pumping it back in,” said Alan Daly, the Canadian manager for TandemHeart. "That allowed the rest of the body to get all the perfusion it needed while we're working away on the chamber that is supposed to do that," Overgaard said, CBCnews reported...

view more

'I'm able to live life again': Toronto doctors complete first-in-Canada heart procedure

CBC News  

2017-04-05

Cardiologist Dr. Christopher Overgaard said Barton's heart was too weak for open-heart surgery. So, the doctor asked if he'd be interested in trying something new...

view more

New device helps doctors perform on weak hearts

CTV News  

Interview

view more

How can doctors be better at communicating? Let patients' families join them on rounds

The Globe and Mail  

2014-06-18

Dr. Christopher B. Overgaard is an interventional cardiologist at the Peter Munk Cardiac Centre in Toronto. He is also the Medical Director of the Coronary Intensive Care Unit (CICU), and Associate Director, Research and Innovation in Interventional Cardiology and Coronary Intensive Care at the University Health Network (UHN).

view more

Articles (5)

Angiographic and Echocardiographic Correlates of Suitable Septal Perforators for Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy


CJC

2014 Myocardial contrast echocardiography during angiography is critical in identifying appropriate septal perforator(s) for alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy. We evaluated whether there were other angiographic and/or echocardiographic markers that might identify patients who are anatomically suitable for ASA.

view more


Hip pain and heart failure: the missing link


Canadian Journal of Cardiology

2013 A man presented with hypothyroidism, dilated cardiomyopathy, a pericardial effusion, liver failure, and polycythaemia. He had a history of bilateral hip replacements and new-onset hip pain. The patient progressed to develop shock. Given his acutely profound ...

view more


Time to Significant Gradient Reduction Following Septal Balloon Occlusion Predicts the Magnitude of Final Gradient Response


JACC Journals

2011 The purpose of this study was to investigate whether a relationship exists between an acute reduction in resting left ventricular outflow tract (LVOT) gradient with balloon occlusion and the final invasive gradient response following alcohol septal ablation (ASA).

view more


The Adverse Long-Term Impact of Renal Impairment in Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era


Circulation: Cardiovascular Interventions.

2009 An observational study determining the long-term impact of chronic kidney disease (CKD) on patients undergoing percutaneous coronary intervention at a tertiary cardiac referral center. CKD is associated with poor in-hospital outcomes after percutaneous coronary intervention, but its effect beyond 1 year, particularly in the drug-eluting stent (DES) era, has not been reported.

view more


Inotropes and vasopressors review of physiology and clinical use in cardiovascular disease


Circulation

2008 Inotropic and vasopressor agents have increasingly become a therapeutic cornerstone for the management of several important cardiovascular syndromes. In broad terms, these substances have excitatory and inhibitory actions on the heart and vascular smooth muscle, as well as important metabolic, central nervous system, and presynaptic autonomic nervous system effects...

view more


 Your profile is not published.

Contact